In medication review module, join Christy Vath, a Physician Assistant at Seattle Rheumatology. Christy provides an overview of the mechanism of action of ixekizumab. This humanized monoclonal antibody targets and neutralizes IL-17A, a pro-inflammatory cytokine involved in autoimmune diseases like psoriasis, psoriatic arthritis, and axial spondylarthritis. By inhibiting IL-17A, ixekizumab helps to modulate the inflammatory response, reducing tissue damage and improving symptoms. For a deeper dive into this topic, visit the RhAPP website's Content Rheum. www.rhapp.org

FAQ #3, in our IL-23i digital education series, "What is the role of the IL23/IL17 axis in rheumatic disease?" is answered by Katie Springer, PA-C

Join host Amanda Mixon, PA-C, and guest Christy Vath, PA-C in this enlightening episode of RhAPPcast. Explore the complex roles of interleukin-23 and interleukin-17 in the development of Psoriatic Arthritis, Psoriasis, and Inflammatory Bowel Disease. Gain insights into how these cytokine pathways influence disease pathogenesis and the promising potential of their targeted inhibition. This episode is an essential listen for those interested in the latest advancements in rheumatology and patient care strategies. Tune in to deepen your understanding and enhance your practice in managing rheumatic diseases.

Join us in this special episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, hosted by Amanda Mixon,PA-C, president of RhAPP. We dive into all the exciting details about the upcoming RhAPP national conference in Nashville, Tennessee, taking place from September 26-28, 2024. Amanda is joined by three esteemed board members, Wendy Simmons, PA-C, Kyle George, PA-C, and Brandon Ko,DNP to discuss new updates, key sessions, networking opportunities, and the vibrant atmosphere attendees can expect.

FAQ #2 in our IL-23 inhibition digital education series is Katie Springer, PA-C Describing the IL23/IL17 axis.

In the first 3-minute journal club of our IL-23 inhibition digital education series, Amber Hudgins, PharmD reviews the ACR abstract: Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23

The first medication review in our IL-23 inhibition digital education series is Danielle Gatti Pharm.D., BCACP, AAHIVP discussing the mechanism of action of guselkumab

FAQ #1 in our IL-23i digital education series is expertly answered by Katie Springer, PA-C